

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14**Bring completed form to:  
File Information Unit, Suite 3A20  
2800 South Randolph Street  
Arlington, VA 22206

Telephone: (703) 756-1800

MAY 16 2011

In re Application of

Application Number

08/536,750

Filed

9/29/95

Paper No.

#18

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified **ABANDONED** application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. \_\_\_\_\_, page, \_\_\_\_\_ line \_\_\_\_\_

United States Patent Number 6346271, column \_\_\_\_\_, line, \_\_\_\_\_

WIPO Pub. No. \_\_\_\_\_, page \_\_\_\_\_, line \_\_\_\_\_

**Related Information About Access to Applications Maintained in the Image File Wrapper System (IFW) and Access to Pending Applications in General**

A member of the public, acting without a power to inspect, cannot order applications maintained in the IFW system through the FIU. If the member of the public is entitled to a copy of the application file, then the file is made available through the Public Patent Application Information Retrieval system (Public PAIR) on the USPTO internet web site ([www.uspto.gov](http://www.uspto.gov)). Terminals that allow access to Public PAIR are available in the Public Search Room. The member of the public may also be entitled to obtain a copy of all or part of the application file upon payment of the appropriate fee. Such copies must be purchased through the **Office of Public Records** upon payment of the appropriate fee (37 CFR 1.19(b)).

For published applications that are still pending, a member of the public may obtain a **copy** of:  
the file contents; the pending application as originally filed; or any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a **copy** of: the file contents; the pending application as originally filed; or any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of the pending application as originally filed.

Ariel Tesfay  
Signature  
Ariel Tesfay  
Typed of printed name

5/16/11  
Date

Registration Number, if applicable

703-486-1150

Telephone Number

**FOR PTO USE ONLY**

Approved by

RECEIVED  
(Initials)

Unit:

May 20 2011

File Information Unit

This collection of information is required by 37 CFR 1.11 and 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Suite 3A20, 2800 South Randolph Street, Arlington, Virginia.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



US006346271B1

(12) **United States Patent**  
**Drizen et al.**

(10) **Patent No.:** **US 6,346,271 B1**  
**(45) Date of Patent:** **\*Feb. 12, 2002**

(54) **TOPICAL DRUG PREPARATIONS**

(75) **Inventors:** **Alan Drizen; Peter Rothbart**, both of  
 Ontario (CA); **Gary M. Nath**,  
 Bethesda, MD (US)

(73) **Assignee:** **L. A. M. Pharmaceutical Corporation**,  
 North York (CA)

(\*) **Notice:** Subject to any disclaimer, the term of this  
 patent is extended or adjusted under 35  
 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-  
 claimer.

(21) **Appl. No.:** **09/288,233**

(22) **Filed:** **Apr. 8, 1999**

**Related U.S. Application Data**

(63) Continuation of application No. 08/796,578, filed on Feb. 6,  
 1997, now Pat. No. 5,897,880, which is a continuation-in-  
 part of application No. 08/536,750, filed on Sep. 29, 1995,  
 now abandoned.

(51) **Int. Cl.<sup>7</sup>** ..... **A61K 9/14**

(52) **U.S. Cl.** ..... **424/484; 424/443; 424/486;**  
**424/496**

(58) **Field of Search** ..... **424/484, 443,**  
**424/486, 496**

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,127,118 A	11/1978	Latorre	
4,521,421 A	6/1985	Foreman	
4,636,524 A *	1/1987	Balazs et al.	514/781
4,801,587 A	1/1989	Voss et al.	
5,015,474 A	5/1991	Parnell	
5,017,229 A *	5/1991	Burns et al.	106/162.2
5,059,603 A	10/1991	Rubin	
5,118,510 A	6/1992	Kuhrts	
5,126,348 A	6/1992	McMurray	
5,143,724 A *	9/1992	Leshchiner et al.	424/78.08
5,190,962 A	3/1993	Barberich et al.	
5,190,967 A	3/1993	Riley	
5,246,702 A	9/1993	Vecchi	
5,256,652 A	10/1993	El-Rashidy	
5,278,192 A	1/1994	Fung et al.	
5,318,780 A *	6/1994	Viegas et al.	424/427
5,333,621 A	8/1994	Denzer	
5,346,935 A *	9/1994	Suzuki et al.	524/18
5,356,629 A *	10/1994	Sander et al.	424/422
5,380,757 A	1/1995	Horrobin	

5,380,758 A	1/1995	Stamler et al.	
5,399,581 A	3/1995	Laragh	
5,474,535 A	12/1995	Place et al.	
5,489,610 A	2/1996	Fung et al.	
5,525,357 A	6/1996	Keefer et al.	
5,527,893 A	6/1996	Burns et al.	
5,565,466 A	10/1996	Gioco et al.	
5,583,144 A	12/1996	Kral	
5,679,394 A	10/1997	Long, Jr. et al.	
5,731,339 A	3/1998	Lowery	
5,741,511 A	4/1998	Lee et al.	
5,897,880 A *	4/1999	Drizen et al.	424/488
6,007,843 A *	12/1999	Drizen et al.	424/488

**FOREIGN PATENT DOCUMENTS**

EP	0266968	10/1987
EP	0346297	5/1989
EP	0539627	10/1991
EP	0516026	5/1992
EP	0581581	7/1993
WO	WO 92/03141	3/1992
WO	WO 93/00894	1/1993

**OTHER PUBLICATIONS**

Allen et al., "Objective Double-blind Evaluation of Erectile  
 Function with Intracorporeal Papaverine in Combination  
 with Phentolamine and/or Prostaglandin E1", *The Journal of*  
*Urology*, 148:1181-83 (1992).

Bennett et al., "An Improved Vasoactive Drug Combination  
 for Pharmacological Erection Program", *The Journal of*  
*Urology*, 146:1564-65 (1991).

Goldstein et al., "Oral Sildenafil in the Treatment of Erectile  
 Dysfunction", *The New England Journal of Medicine*, vol.  
 338, No. 20:1397-1404 (1998).

Lakin et al., "Intracavernous Injection Therapy: Analysis of  
 Results and Complications", *The Journal of Urology*,  
 143:1138-41 (1990).

Valdevenito et al., "Intracavernous Self-Injection Pharma-  
 cotherapy Program: Analysis of Results and Complica-  
 tions", *Int. J. Impotence Res.*, 6:81-91 (1994).

MUSW® (Alprostadil) (*package insert*), Vivu Inc. (1996).

\* cited by examiner

*Primary Examiner*—Diana Dudash

*Assistant Examiner*—Mina Haghighatian

(74) *Attorney, Agent, or Firm*—Nath & Associates PL;  
 Gary M. Nath

(57) **ABSTRACT**

Topical gelled compositions comprising an optional drug  
 dispersed within a polymer matrix, methods of producing  
 the same and treatments with the complex.

**12 Claims, No Drawings**